Financial intelligence for Asia's healthcare markets
Remember me:

Analysis: Private equity flocks to healthcare

Amid questions about the direction of the global economy, investors doubled down on healthcare as a safe haven in 2016, driving up both the number and the value of deals, according to Bain & Company’s sixth Global Healthcare Private Equity and Corporate M&A Report.

Yet, with so much interest in overall healthcare assets, they faced intense competition for deals. This heated struggle bid up valuations and forced healthcare investors to get creative. Many funds took advantage of a disparity between public and private valuations for some healthcare assets, which prompted a surge in public-to-private transactions. The flip side of this trend was a falloff in the number of IPOs, amid a modest decline in overall exit activity.

In sharp contrast to the broader decline in PE deal-making, healthcare PE activity soared globally with disclosed deal values reaching US$36.4 billion in 2016, its highest level since 2007. That marked a nearly 60% increase from the total of US$23.1 billion in 2015. In Asia Pacific, activity was also strong, especially in the provider sector where deal count nearly tripled and there were a total of 52 buyouts, a return to levels last seen in 2013.

“As a long-term bet, healthcare is hard to beat,” said Kara Murphy, a partner in Bain’s Global Healthcare and Private Equity Practices and co-author of the report. “Deal activity will continue to be high as more funds look to deploy capital into the sector. Given the intense competition, funds will need to be increasingly creative to get deals done.”

After three consecutive record-setting years, total deal value in the Asia Pacific region declined somewhat in 2016, to US$3.2 billion from US$4.9 billion in 2015. The falloff was largely due to the lack of a megadeal such as the US$3.3 billion buyout of publicly traded WuXi PharmaTech that dominated 2015. The few mega scale assets that became available in 2016 went to corporate buyers. That said, underlying momentum was strong, with 10 buyouts last year valued at more than US$100 million and an additional US$700 million of the region’s capital was deployed in private investments in public equities.

PE investors continue to find Asia-Pacific’s demographics promising supported by both a growing and aging population, an expanding middle-class and rising burden of both chronic and communicable diseases. This resurgence in deal activity across the region was led by the provider sector, with 31 provider deals in 2016, about three times the number in 2015.

“Healthcare is becoming a go to destination for financial investors in Asia Pacific” said Vikram Kapur, Bain partner and leader of the firms APAC Healthcare practice. “The attractive fundamentals of the sector are bolstered by the fact that, today, assets in the region are reaching the scale that gets more and more PE investors to take notice.”

So what should we expect this year?

“Investors can expect more volatility in 2017,” said Nirad Jain, a partner in Bain’s Global Healthcare and Private Equity Practices and the report’s co-author. “As the turmoil continues, so too will the attractiveness of healthcare as a safe-haven investment. With an aging and ailing global population, demand for healthcare services will rise regardless of whether there are economic headwinds, tailwinds or crosswinds. But, that’s not to say all healthcare investors will have smooth sailing – sky-high valuations for healthcare assets mean that there are choppy waters to navigate.”

In this environment, deal makers will need to continue to be creative and look harder to find targets that have the capacity to deliver meaningful returns.

“In Asia Pacific, the coming of age of assets and growing competition from PE and corporates will continue to raise the bar for investors and they will need to think hard about the differential value add they can bring to targets beyond growth capital” added Kapur.

Posted on: 20/04/2017 UTC+08:00


News

Beijing-based healthcare service platform Miaoshou Doctor has completed a ¥1.5 billion (US$232 million) Series F round of financing.
Chinese digital technology company, Xisoft Technology, which focuses on hospital operation management, has raised ¥100 million ($15.65 million) in Series A+ financing.
Hearing health company Olive Union has closed a $7M Series B round led by Beyond Next Ventures, Bonds Investment Groups and Japan Policy Finance Corporation.
Long Hill Capital, a venture capital firm in China, has closed on more than $300 million for its third fund on 15 March.
Eluminex Biosciences, an ophthalmic biotechnology company has completed a $50 million Series A financing co-led by Lilly Asia Ventures, GL Ventures (venture capital arm of Hillhouse Capital), and Quan Capital.
TVM Capital Healthcare, a global private equity and growth capital firm focused on emerging markets, has announced two team additions today.
In partnership with VeChain and DNV GL, Renji Hospital, a hospital in China affiliated with the Shanghai Jiaotong University School of Medicine, has launched the world's first blockchain-enabled intelligent tumour treatment centre.
Hong Kong-based BuyHive, a new global sourcing start-up that connects buyers with trusted verified overseas suppliers, has launched a PPE programme to help US companies optimise their post-Covid supply chains.



Analysis

L.E.K. Consulting’s Fabio La Mola tells HealthInvestor Asia about a healthcare market going through major changes – creating significant opportunities for investors in the region.
Edwin Tong, senior minister for health, explains how the Ministry of Health in Singapore is supporting the growth in the number of seniors with Alzheimer's.
Penny Wan, regional vice-president and general manager, Japan and APAC, Amgen, writes about the public health challenge of cardiovascular diseases.
French-based international ophthalmic optics company Essilor has signed Letters of Intent with the Royal Government of Bhutan and the Central Monastic Body to strengthen the country’s vision care infrastructure.
April Chang, country manager at Cigna Singapore, argues that wellness programmes at work can lead to reduced absenteeism, higher productivity and increased morale among employees.
Steven Fang understands how to set up a healthcare company. Not only is he chief executive and founder of ASX-listed oncology company Invitrocue, he was also the founder of Singapore-based Cordlife Group, a healthcare company which provides cord blood and cord lining banking services.
Imagine a world in which you can consult with your doctor via video. She asks for a blood sample, which can be collected and analysed from a device in your home. After that is diagnosed, the prescription is automatically sent to the pharmacy and Uber then picks it up. The time from diagnosis to drugs at your home is only 60 minutes.
The digitisation of health data through blockchain technology is a groundbreaking solution that will empower patients and provide them with better access to healthcare.


Podcasts

HealthInvestor Asia twitter feed










A Rolex Yacht-Master I Ladies Replica watch is basically a person watch that's crafted inside an identical fashion with a well-known maker¡¯s real piece. Purchasing Replica Watches seems as an excellent idea. Anyway,ON perfectcloneshop.com replica Rolex Yacht-Master Ladies watches are affordable, look almost the identical while using real ones and could easily acquired.